综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Innovation

Chinese scientists develop novel hydrogel for post-surgical cancer treatment

Xinhua | Updated: 2018-03-20 23:29
Share
Share - WeChat

BEIJING - One of the biggest problems for cancer patients is the high recurrence rates after surgery. But a novel hydrogel recently developed by Chinese scientists has proved helpful in eliminating residual tumor tissues and preventing infection.

A team of researchers from Shenzhen Institutes of Advanced Technology published their findings in the journal "Advanced Science" earlier this month, highlighting the efficacy of the black phosphorus (BP) incorporated hydrogel in the photothermal platform.

Cancer patients often blame radiotherapy and chemotherapy for their serious complications and side effects. More and more people are opting for photothermal therapy (PTT).

"PTT can treat cancer with minimal invasivessness, yet it has been stifled in clinical adoption for the insufficient biodegradability of the PTT agents. Our hydrogel tackles this problem," said Yu Xuefeng, the leading researcher of the team.

In their work, a new PTT system is designed by incorporating BP nanosheets with a thermosensitive hydrogel for the postoperative photothermal treatment of cancer.

Yu said that the newly developed hydrogel had excellent near infrared (NIR) photothermal performance and good biodegradability and biocompatibility in vitro and in vivo.

Based on these merits, researchers have developed an in vivo PTT treatment strategy for postsurgical treatment.

"Under NIR irradiation, the sprayed BP hydrogel can rapidly form a gelled membrane on wounds and help eliminate residual tumor tissues after tumor removal surgery," Yu said.

The hydrogel's antibacterial performance prevents infection in treatment and improves the efficacy of PTT, according to the findings.

"Now the hydrogel is a patent pending product. Our team is filing for a clinical adoption license in hope that the product can be applied for clinical uses at an earlier time," Yu said.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
宝丰县| 且末县| 白山市| 抚顺县| 昆明市| 全南县| 中西区| 佛冈县| 绥化市| 洪江市| 临沭县| 留坝县| 鹤壁市| 建德市| 讷河市| 彭泽县| 吉林市| 仪陇县| 瑞金市| 吉木萨尔县| 阳信县| 洪湖市| 郧西县| 大冶市| 襄樊市| 高平市| 股票| 和静县| 耿马| 湘潭市| 阿城市| 噶尔县| 泰安市| 定襄县| 太谷县| 海门市| 云阳县| 元谋县| 霍邱县| 崇信县| 上林县|